Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.18 by 161.11 percent. This is a 158.75 percent increase over losses of $(0.80) per share from the same period last year. The company reported quarterly sales of $238.946 million which beat the analyst consensus estimate of $216.456 million by 10.39 percent. This is a 19.58K percent increase over sales of $1.214 million the same period last year.